AR100680A1 - Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos - Google Patents

Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos

Info

Publication number
AR100680A1
AR100680A1 ARP150101706A ARP150101706A AR100680A1 AR 100680 A1 AR100680 A1 AR 100680A1 AR P150101706 A ARP150101706 A AR P150101706A AR P150101706 A ARP150101706 A AR P150101706A AR 100680 A1 AR100680 A1 AR 100680A1
Authority
AR
Argentina
Prior art keywords
molecules
antibodies
binding
same
molecule
Prior art date
Application number
ARP150101706A
Other languages
English (en)
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AR100680A1 publication Critical patent/AR100680A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se dirige al mAb 1 y mAb 2 del anticuerpo anti-DR5, y a versiones humanizadas y quiméricas de tales anticuerpos. Adicionalmente a moléculas de unión de DR5 que comprenden fragmentos de tales moléculas, y a moléculas biespecíficas que incluyen diacuerpos, BiTEs, anticuerpos biespecíficos de protuberancias / agujeros, etc., que; comprenden: (i) tales fragmentos de unión de DR5 y (ii) un dominio capaz de unirse a un epítopo de una molécula presente sobre la superficie de una célula efectora. Reivindicación 31: La molécula de unión de DR-5 anti-humano de conformidad con cualquiera de las reivindicaciones 1 - 30, caracterizada porque la molécula se utiliza en el tratamiento de cáncer.
ARP150101706A 2015-01-26 2015-05-29 Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos AR100680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562107786P 2015-01-26 2015-01-26

Publications (1)

Publication Number Publication Date
AR100680A1 true AR100680A1 (es) 2016-10-26

Family

ID=56544107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101706A AR100680A1 (es) 2015-01-26 2015-05-29 Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos

Country Status (3)

Country Link
AR (1) AR100680A1 (es)
TW (1) TW201627322A (es)
WO (1) WO2016122701A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907648XA (en) * 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding gd2, nkg2d and cd16
US11884732B2 (en) * 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
CA3064743A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and ror1 or ror2
EP3630181A4 (en) * 2017-05-23 2021-03-17 Dragonfly Therapeutics, Inc. NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN
KR20200010430A (ko) * 2017-05-23 2020-01-30 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
BR112020003050A2 (pt) * 2017-08-16 2020-09-01 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16, e egfr, hla-e, ccr4 ou pd-l1
WO2019094533A1 (en) 2017-11-10 2019-05-16 Ngm Biopharmaceuticals Inc Angptl8-binding agents and methods of use thereof
CN109836500A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109957024A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109957020A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
BR112020016190A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Domínios variáveis de anticorpos direcionando o receptor nkg2d
US20210079102A1 (en) * 2018-02-08 2021-03-18 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP2021523140A (ja) * 2018-05-07 2021-09-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合するタンパク質
EP4139361A4 (en) * 2020-04-23 2024-05-15 Baylor College of Medicine OVERCOMING THE TUMOR MICROENVIRONMENT FOR CELLULAR THERAPY BY TARGETING MYELOID-DERIVED SUPPRESSOR CELLS VIA A SPECIFIC TRAIL-R2 RECEPTOR
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2024083021A1 (zh) * 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
KR20120001684A (ko) * 2010-06-29 2012-01-04 성균관대학교산학협력단 투명 전도성막, 이의 제조 방법, 및 이를 이용한 투명전극 및 소자
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response

Also Published As

Publication number Publication date
TW201627322A (zh) 2016-08-01
WO2016122701A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
AR100680A1 (es) Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
CO2017012553A2 (es) Moléculas de unión a lag-3
CY1124634T1 (el) Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων
CL2021003535A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019)
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
PH12018501554A1 (en) Ror1 antibody compositions and related methods
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
PE20180950A1 (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
EA201791270A1 (ru) Модифицированные april-связывающие антитела
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PE20190737A1 (es) Anticuerpos anti-cd27
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
CL2018001238A1 (es) Moléculas de unión específicas para asct2 y usos de las mismas
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
AR096445A1 (es) Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga

Legal Events

Date Code Title Description
FB Suspension of granting procedure